Teitur Trophics has announced successful results from its Phase I clinical trial of lead asset TT-P34 in healthy volunteers and patients with early-stage Parkinson’s disease (PD). 

The data show TT-P34 crosses the blood-brain barrier, leading to robust, dose-dependent exposure within the brain and central nervous system (CNS). 

The positive results support the company’s plans to initiate a Phase II trial in PD patients in 2027, which will be designed to explore the therapeutic benefit and disease modifying potential of TT-P34. 

TT-P34 is a first-in-class therapy that, through a dual mechanism of action, improves both mitochondrial and lysosomal function. Its unique mode of action, targeting a critical pathway that underpins multiple aspects of pathology, means TT-P34 also has potential as a disease-modifying drug for other neurodegenerative conditions including frontotemporal dementia and Huntington’s disease. 

Andreas Borta, Chief Medical Officer of Teitur Trophics, said: “These data show TT-P34 – which is potentially a game-changer not just for Parkinson’s disease but a range of other neurodegenerative diseases as well – has an excellent safety profile and is well-tolerated, enters the brain and CNS as expected, and has excellent pharmacokinetics. The biomarker data, which indicate engagement of the lysosomal pathway, are also highly encouraging.” 

Simon Mølgaard, Co-Founder & Chief Executive Officer of Teitur Trophics, added: “These are remarkable results from our Phase I clinical trial of TT-P34 in healthy volunteers and patients with early-stage Parkinson’s disease. We are now fundraising for a Series B investment round ahead of our planned Phase II study of TT-P34 in Parkinson’s. Disease-modifying treatments for Parkinson’s, a condition that seriously affects over 10 million people worldwide, are desperately needed as we can still only manage its symptoms.”